Bausch + Lomb to operate as independent unit after acquisition, officials say

KIAWAH ISLAND, S.C. - Bausch + Lomb will continue to operate independently, even after Valeant Pharmaceuticals acquires the global ophthalmology business for $8.7 billion, according to company representatives. The agreement for the cash transaction was announced in a joint press release from the two companies May 27.“We are still Bausch + Lomb. We will continue to do all our business as Bausch + Lomb,” Calvin W. Roberts, MD, Bausch + Lomb’s chief medical officer, said in an interview with Ocular Surgery News here. Furthermore, new parent company Valeant has reassured (Read more...)

Full Story →